Aurinia Pharmaceuticals (AUPH) Capital Leases (2023 - 2026)

Aurinia Pharmaceuticals' Capital Leases history runs 4 years deep, the most recent figure standing at $48.2 million for Q1 2026.

• Quarterly Capital Leases fell 15.22% year-over-year to $48.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (down 15.22% YoY) and the FY2025 annual result came in at $52.3 million, down 10.64% from the prior year.
• Capital Leases was $48.2 million for Q1 2026 at Aurinia Pharmaceuticals, down from $52.3 million in the prior quarter.
• Across five years, Capital Leases topped out at $79.4 million in Q2 2023 and bottomed at $48.2 million in Q1 2026.
• A 4-year average of $63.0 million and a median of $62.1 million in 2024 frame the typical range for Capital Leases.
• Peak annual rise in Capital Leases reached 8.64% in 2024, while the deepest fall reached 22.42% in 2024.
• Aurinia Pharmaceuticals' Capital Leases stood at $75.5 million in 2023, then dropped by 22.42% to $58.6 million in 2024, then declined by 10.64% to $52.3 million in 2025, then retreated by 7.91% to $48.2 million in 2026.
• Business Quant data shows AUPH's Capital Leases at $48.2 million in Q1 2026, $52.3 million in Q4 2025, and $55.7 million in Q3 2025.